|
Match
|
Document |
Document Title |
|
|
US20090312414 |
Treatment Of Lower Urinary Tract Dysfunction With CB2-Receptor-Selective Agonists
A method is disclosed utilizing a cannabinoid receptor type 2-receptor-selective agonist for treating or preventing lower urinary tract dysfunction, including overactive bladder, lower urinary...
|
|
|
US20090306212 |
Compositions and Methods for Treating Diabetes and Neuropsychological Dysfunction
The present invention relates to compositions and methods for treating diabetes mellitus, neuropsychological and neurological disorders in a particular group of patient. More specifically, the...
|
|
|
US20090298742 |
PROCESS FOR MANUFACTURING LACTOSE
A process for forming crystalline lactose suitable for use in a pharmaceutical formulation comprises subjecting a solution comprising a plurality of nanosized lactose particles to conditions...
|
|
|
US20090275556 |
Aryl sulfonamides useful as inhibitors of chemokine receptor activity
The present invention provides compounds of general formula I:
or a pharmaceutically acceptable salt thereof, wherein R 1 , X, Z, R 2 , X 1 , Ar, n, R 3 and R 4 are defined generally and in...
|
|
|
US20090264533 |
Methods and Compositions for Modulating RHO-Mediated Gene Transcription
The present invention is directed to methods and compositions methods and compositions for determining and inhibiting gene transcription in mammalian cells. The invention relates to novel...
|
|
|
US20090247627 |
AMINO- AND AMIDO-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS
The invention provides amino- and amido-aminotetralin compounds of formula (I):
wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and n are defined in the specification, or a...
|
|
|
US20090234014 |
Naphthalene-Disulfonamides Useful for the Treatment of Inflammation
There is provided compounds of formula (I), wherein R 1 , R 2 , X 2 , X 4 and X 5 to X 8 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds...
|
|
|
US20090233909 |
Sulfonamide compounds as cysteine protease inhibitors
The present invention is directed to compounds of formula (I) that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases...
|
|
|
US20090227571 |
Androgen Receptor Modulator Compounds and Methods
Provided herein are compounds that bind to androgen receptors and modulate the activity and/or the amount of androgen receptors and to methods for making and using such compounds. Also provided are...
|
|
|
US20090221711 |
TRIFLUOROMETHYL-CONTAINING PHENYLSULFONAMIDE BETA AMYLOID INHIBITORS
A compound of Formula (I), or pharmaceutically acceptable salts and/or hydrates or prodrugs thereof, wherein Formula (I) has the structure:
is provided, wherein R 1 -R 7 are defined herein....
|
|
|
US20090186107 |
Orally Administrable Films and Preparation Thereof
The invention relates to an orally administrable mucoadhesive film which comprises one or more bioactive ingredients and, as a major film-forming polymer, at least one alginate which is capable of...
|
|
|
US20090170950 |
Inhibitors Of Neurotrypsin
The invention relates to a method for determining whether a compound is a neurotrypsin inhibitor, characterized in that the compound is incubated together with neurotrypsin, a variant thereof or a...
|
|
|
US20090163487 |
N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS
The invention relates to N-hydroxylsulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of...
|
|
|
US20090163575 |
SOLVENT SYSTEMS FOR POUR-ON FORMULATIONS FOR COMBATING PARASITES
This invention relates to pharmaceutical and veterinary formulations providing enhanced solvency and stability for pharmaceutical and veterinary agents for administration to animals, especially...
|
|
|
US20090163509 |
Method for healing a wound using an alpha-adrenergic antagonist
A method for healing a wound comprising the step of topically administering a wound healing composition to a wounded area, wherein the wound healing composition comprises a first medicament...
|
|
|
US20090155343 |
Tamsulosin-Containing Transdermal Patch
A tamsulosin-containing transdermal patch. A transdermal patch comprising a backing-layer and an adhesive layer on the backing-layer, characterized in that the adhesive layer contains an acrylic...
|
|
|
US20090137681 |
Sirtuin Inhibiting Compounds
Provided herein are compositions and methods for treating or preventing cancer and autoimmune diseases. Compositions comprise a sirtuin inhibitory compound that decreases the activity of a sirtuin,...
|
|
|
US20090130180 |
Preparation for External Use
A preparation for external use which, even when ingredients such as a drug, absorption accelerator, and plasticizer are contained therein in a large amount, is excellent in pressure-sensitive...
|
|
|
US20090130200 |
GRANULES FOR CONTROLLED RELEASE OF TAMSULOSIN
Granules for controlled release of Tamsulosin, the granules including Tamsulosin and a carrier matrix. The carrier matrix includes a) 2 to 25% by weight of an alginate and b) 30 to 70% by weight of...
|
|
|
US20090117040 |
Novel pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases
The present invention relates to pharmaceutical and diagnostic compositions as well as to the use of the active substances contained therein for preparing a pharmaceutical or a diagnostic...
|
|
|
US20090105309 |
Medicinal Compounds
Compounds of formula (I):
and salts, solvates, and physiologically functional derivatives thereof, useful for the prophylaxis or treatment of a clinical condition for which a selective β 2...
|
|
|
US20090099187 |
Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor
The present invention relates to new compounds of formula (I), wherein R 1 to R 12 , P, X, Q and n are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their...
|
|
|
US20090093525 |
Cyclopropyl aryl amide derivatives and uses thereof
Compounds of the formula:
wherein Ar 1 , Ar 2 , R 1 and R 2 are as defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the subject compounds.
|
|
|
US20090076021 |
THERAPEUTIC COMBINATIONS AND METHODS FOR CARDIOVASCULAR IMPROVEMENT AND TREATING CARDIOVASCULAR DISEASE
A therapeutic combination, useful in a co-therapy method for improving cardiovascular performance and/or treating cardiovascular diseases, is provided comprising a first agent and a second agent,...
|
|
|
US20090069302 |
CHEMICAL COMPOUNDS
The present invention relates generally to novel therapeutic compounds and AXOR 109 agonists, and processes for the manufacture and use of the same.
|
|
|
US20090048156 |
HDAC INHIBITORS AND HORMONE TARGETED DRUGS FOR THE TREATMENT OF CANCER
The present invention relates to the methods of treating endocrine-regulated cancers, including hormone resistant cancers, for example. More specifically, the present invention relates to a method...
|
|
|
US20090035372 |
METHOD FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE OF AN ACTIVE SUBSTANCE
The present invention pertains to a sized product, which contains a drug, polyethylene oxide with a molecular weight of 2,000,000 or higher, and a specific size controlling agent for polyethylene...
|
|
|
US20090012115 |
USE OF TP MODULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS IN ASPIRIN SENSITIVE AND OTHER POPULATIONS
The present invention provides methods and compositions useful in the treatment or prevention of cardiovascular disorders in individuals for whom therapy with a COX-1 enzyme inhibitor is not...
|
|
|
US20090004284 |
Controlled release tamsulosin hydrochloride formulation
The present invention relates to a controlled release pellet of tamsulosin and its pharmaceutically acceptable salts that comprise an inert starting seed or core.
|
|
|
US20080318996 |
6-Amino(Aza)Indane Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor
The present invention relates to 6-amino(aza)indane compound of the formula (I) Wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical R...
|
|
|
US20080312328 |
DEUTERIUM-ENRICHED TAMSULOSIN
The present application describes deuterium-enriched tamsulosin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
|
|
|
US20080300280 |
Cyanobenzene Compounds for Combating Animal Pests
The present invention relates to a method of combating animal pests which comprises contacting the animal pests, their habit, breeding ground, food supply, plant, seed, soil, area, material or...
|
|
|
US20080262089 |
Process for the Preparation of Tamsulosin
The invention includes an improved process for producing tamsulosin comprising reacting 5-(2-aminopropyl)-2-methoxybenzenesulfonamide with 2-(o-ethoxyphenoxy)ethyl bromide in an organic phosphite...
|
|
|
US20080213399 |
Combination Therapies Using Hdac Inhibitors
The present invention pertains to a method for treating cancer, such as lung cancer, multiple myeloma, lymphoma, and epithelial ovarian cancer, comprising the administration to a patient in need...
|
|
|
US20080206378 |
Anthelmintic Composition
A topical formulation comprising as active ingredients, at least one effective agent derived from Streptomyces avermitilis , i.e. a macrocylic lactone e.g. an avermectin or chemically modified or...
|
|
|
US20080207584 |
Compound Having S1P Receptor Binding Potency and Use Thereof
Provided are: a compound represented by formula (I):
(wherein ring A and ring D each represent a cyclic group which may have a substituent(s); E and G each represent a bond or a spacer having 1...
|
|
|
US20080200499 |
Selective Insecticides and/or Acaricides Based on Substituted Cyclic Dicarbonyl Compounds and Safeners
The present invention relates to the use of selective insecticidal and/or acaricidal compositions, characterized in that they comprise an effective amount of an active compound combination...
|
|
|
US20080194691 |
Apoptosis Promoters
Compounds of formula (I), in which B 1 and X 1 are together alkylene which is unsubstituted or substituted with ═O and having one CH2 moiety unreplaced or replaced with CH═CH, O, NH or...
|
|
|
US20080194404 |
Sulphonyl Compounds for Seed Treatment
The present invention provides a method for the protection of seeds from soil insects and of the seedlings' roots and shoots from soil and foliar insects comprising contacting the seeds before...
|
|
|
US20080194690 |
Pharmaceutical Formulations Of Hdac Inhibitors
This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N...
|
|
|
US20080182906 |
Novel Specific Caspase-10 Inhibitors
The invention relates to compounds of the general formula (I) wherein R1, R2, R3, R4, R5, R6, i and j have the meanings given in claim 1, and to the use thereof as caspase-10 inhibitors,...
|
|
|
US20080176842 |
BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS
Bis-sulfonamido hydroxyethylamino compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to retroviral protease...
|
|
|
US20080159955 |
CA IX-Specific Inhibitors
Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds,...
|
|
|
US20080153830 |
ALPHA AND/OR BETA-ADRENERGIC ANTAGONISTS AND AGONISTS TO TREAT PAIN
The present disclosure provides for improved methods for treating pain, including pain associated with chronic inflammatory diseases, neuropathic pain and cancer by using α-adrenergic antagonists...
|
|
|
US20080119555 |
Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions
The present invention pertains to certain aryl alkyl sulfonamides and derivatives thereof which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption,...
|
|
|
US20080113030 |
Sustained release tamsulosin formulations
A sustained release tamsulosin formulation contains tamsulosin, a hydrophobic polymer, a microsphere forming agent and a diluent. The hydrophobic polymers include pH-dependent and pH-independent...
|
|
|
US20080069850 |
Multicomponent bioactive intravaginal ring
Intravaginal ring devices have multicomponent drug releasing substrates loaded with at least one bioactive agent and designed to effect contraception and/or provide means to treat and/or prevent...
|
|
|
US20080063678 |
Novel 2-Cyano-3(Halo)Alkoxy-Benzenesulfonamide Compounds for Combating Animal Pests
The invention relates to 2-cyano-3-(halo)alkoxy-benzenesulfonamide compounds I
where the variables Alk and R 1 to R 5 are as defined in claim 1, and/or to their agriculturally useful...
|
|
|
US20080051416 |
Novel Compounds
The present invention is directed to novel compounds of formula (I):
or pharmaceutically acceptable derivatives thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.
|
|
|
US20080039428 |
Antiretroviral combination therapy
The present invention provides combinations comprising a viral maturation inhibitor and another therapeutically effective pharmaceutical agent. The invention is also directed to methods of treating...
|